Please use this identifier to cite or link to this item:
http://dx.doi.org/10.25673/115600
Title: | SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition |
Author(s): | Fischer, Claudia Willscher, Edith Paschold, Lisa Gottschick, Cornelia Klee, Bianca Diexer, Sophie Bosurgi, Lidia Dutzmann, Jochen ![]() Sedding, Daniel ![]() Frese, Thomas ![]() Girndt, Matthias ![]() Höll, Jessica ![]() Gekle, Michael ![]() Addo, Marylyn M. ![]() Schulze zur Wiesch, Julian Constantin Raimar ![]() Mikolajczyk, Rafael ![]() Binder, Mascha ![]() Schultheiß, Christoph ![]() |
Issue Date: | 2024 |
Type: | Article |
Language: | English |
Abstract: | The rapid development of safe and effective vaccines helped to prevent severe disease courses after SARS-CoV-2 infection and to mitigate the progression of the COVID-19 pandemic. While there is evidence that vaccination may reduce the risk of developing post-COVID-19 conditions (PCC), this effect may depend on the viral variant. Therapeutic effects of post-infection vaccination have been discussed but the data for individuals with PCC remains inconclusive. In addition, extremely rare side effects after SARS-CoV-2 vaccination may resemble the heterogeneous PCC phenotype. Here, we analyze the plasma levels of 25 cytokines and SARS-CoV-2 directed antibodies in 540 individuals with or without PCC relative to one or two mRNA-based COVID-19 vaccinations as well as in 20 uninfected individuals one month after their initial mRNA-based COVID-19 vaccination. While none of the SARS-CoV-2 naïve individuals reported any persisting sequelae or exhibited PCC-like dysregulation of plasma cytokines, we detected lower levels of IL-1β and IL-18 in patients with ongoing PCC who received one or two vaccinations at a median of six months after infection as compared to unvaccinated PCC patients. This reduction correlated with less frequent reporting of persisting gastrointestinal symptoms. These data suggest that post-infection vaccination in patients with PCC might be beneficial in a subgroup of individuals displaying gastrointestinal symptoms. |
URI: | https://opendata.uni-halle.de//handle/1981185920/117553 http://dx.doi.org/10.25673/115600 |
Open Access: | ![]() |
License: | ![]() |
Journal Title: | npj vaccines |
Publisher: | Nature Publishing Group |
Publisher Place: | [London] |
Volume: | 9 |
Original Publication: | 10.1038/s41541-024-00815-1 |
Page Start: | 1 |
Page End: | 11 |
Appears in Collections: | Open Access Publikationen der MLU |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s41541-024-00815-1.pdf | 2.32 MB | Adobe PDF | ![]() View/Open |